These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26927176)

  • 1. Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer.
    Richter AM; Walesch SK; Dammann RH
    Cancers (Basel); 2016 Feb; 8(3):. PubMed ID: 26927176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter methylation status of Ras-association domain family members in pheochromocytoma.
    Richter AM; Zimmermann T; Haag T; Walesch SK; Dammann RH
    Front Endocrinol (Lausanne); 2015; 6():21. PubMed ID: 25750636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancer.
    Richter AM; Walesch SK; Würl P; Taubert H; Dammann RH
    Oncogenesis; 2012 Jun; 1(6):e18. PubMed ID: 23552700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer.
    Dong T; Zhang M; Dong Y; Herman JG; van Engeland M; Zhong G; Guo M
    Discov Med; 2015 Nov; 20(111):261-71. PubMed ID: 26645898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer.
    Richter AM; Kiehl S; Köger N; Breuer J; Stiewe T; Dammann RH
    Clin Epigenetics; 2017; 9():60. PubMed ID: 28588743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.
    Schagdarsurengin U; Richter AM; Wöhler C; Dammann RH
    Epigenetics; 2009 Nov; 4(8):571-6. PubMed ID: 19934646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
    Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
    Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.
    Richter AM; Woods ML; Küster MM; Walesch SK; Braun T; Boettger T; Dammann RH
    Oncogene; 2020 Apr; 39(15):3114-3127. PubMed ID: 32047266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RASSF10 is epigenetically inactivated and induces apoptosis in lung cancer cell lines.
    Wang Y; Ma T; Bi J; Song B; Zhou Y; Zhang C; Gao M
    Biomed Pharmacother; 2014 Apr; 68(3):321-6. PubMed ID: 24433832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
    Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
    J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway.
    Li X; Liang Q; Liu W; Zhang N; Xu L; Zhang X; Zhang J; Sung JJ; Yu J
    Oncogene; 2016 May; 35(19):2453-64. PubMed ID: 26279301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation in promoter regions of PITX2 and RASSF1A genes in association with clinicopathological features in breast cancer patients.
    Jezkova E; Kajo K; Zubor P; Grendar M; Malicherova B; Mendelova A; Dokus K; Lasabova Z; Plank L; Danko J
    Tumour Biol; 2016 Oct; ():. PubMed ID: 27744628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma.
    Liu W; Wang J; Wang L; Qian C; Qian Y; Xuan H; Zhuo W; Li X; Yu J; Si J
    Oncogenesis; 2016 Jun; 5(6):e237. PubMed ID: 27348267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
    Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
    Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
    Dammann R; Yang G; Pfeifer GP
    Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Tumor Suppressor Role of the Ras Association Domain Family 10.
    Hou Y; Li S; Du W; Li H; Wen R
    Anticancer Agents Med Chem; 2020; 20(18):2207-2215. PubMed ID: 32664845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.